Supriya Lifescience Corporate Filings & Announcements

Pharmaceuticals company Supriya Lifescience announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs 184.11 crore compared to Rs 158.18 crore in Q4FY24. EBITDA for Q4FY25 stood at Rs 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs 55.5 crore in Q4FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY. Profit after Tax for Q4FY25 stood at Rs 50.38 crore, with a growth of 38.4% compared to Rs 36.40 crore in Q4FY24. The PAT Margin stood at 27.4% in Q4FY25, compared to 23.0% in Q4FY24 FY25 Financial Highlights: In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs 696.48 crore compared to Rs 570.37 crore in FY24. EBITDA for FY25 stood at Rs 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY. Profit after Tax for FY25 stood at Rs 187.96 crore, with a growth of 57.8% compared to Rs 119.11 crore in FY24. The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience commenting on the results, said, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of Rs 697 crore, up 22% year-on-year, and delivered an EBITDA of Rs 261 crore with a robust margin of 37.4%. In Q4FY25, revenue grew by 16.4% to Rs 184.11 crore, while PAT rose by 38.4% to Rs 50.38 crore, supported by improved margins. Our strategic focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.” Result PDF

34.59% Gain from 52W Low

Supriya Lifescience Corporate Filings & Announcements

Latest corporate announcements and filings from Supriya Lifescience on BSE